Omaveloxolone attenuates the sepsis-induced cardiomyopathy via activating the nuclear factor erythroid 2-related factor 2.
Sign Up to like & getrecommendations! Published in 2022 at "International immunopharmacology"
DOI: 10.2139/ssrn.4115193
Abstract: Sepsis-induced cardiomyopathy (SIC) is a common complication of sepsis and is the main reason for the high mortality in sepsis patients. More recent studies have indicated that activating nuclear factor erythroid 2-related factor 2 (Nrf2)… read more here.
Keywords: sepsis; factor; induced cardiomyopathy; activating nuclear ... See more keywords
Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates
Sign Up to like & getrecommendations! Published in 2019 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s193889
Abstract: Background Omaveloxolone is a synthetic oleanane triterpenoid that pharmacologically activates Nrf2, a master transcription factor that regulates genes with antioxidative, anti-inflammatory, and mitochondrial bioenergetic properties, and is being evaluated in patients with Friedreich’s ataxia. Methods… read more here.
Keywords: omaveloxolone; friedreich ataxia; ataxia patients; oral administration ... See more keywords